BioCryst Pharma (NASDAQ:BCRX) Rating Increased
In a research note released on Tuesday, 2 January, RBC Capital boosted shares of Biocryst Pharma (NASDAQ:BCRX) to Outperform rating from Sector Perform rating.
Despite this stock rating upgrade NASDAQ:BCRX is currently trading -3.54% lower at $4.91 as of 10:07 PM New York time. BioCryst Pharma’s stock is 0% in the last 200 days. It has underperformed the S&P 500, which has added 6.00% in the same time.
Rtw Investments Llc had the most significant stake with ownership of 4.20M shares as of q2 2015 for 5.6% of the US long stock exposure. Vhcp Management Llc is another notably bullish active investment manager who is having 1.01M shares of BioCryst Pharma or 4.36% of their US long stock exposure. Further, Ra Capital Management Llc have 1.36% of their US long stock exposure invested in the company for 2.99M shares. The New York-based fund Ghost Tree Capital Llc disclosed it had acquired so far a stake worth about 1.29% of the active investment manager’s stock portfolio in BioCryst Pharma. The California-based fund Venbio Select Advisor Llc is also positive about the stock, possessing 1.80M shares or 1.07% of their US long stock exposure.
BioCryst Pharma (NASDAQ:BCRX) Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases.
BioCryst Pharma (NASDAQ:BCRX) traded down -3.54% on 2 January, hitting $4.91. A total of 500 shares of the company’s stock traded hands. This is down from average of 1.03 million shares. BioCryst Pharma has a 52 week low of $3.95 and a 52 week high of $9.25. The company has a market cap of $500.88 million and a P/E ratio of 0.
Get the latest BioCryst Pharma (NASDAQ:BCRX) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post BioCryst Pharma (NASDAQ:BCRX) was Increased at RBC Capital from a Sector Perform Rating to Outperform appeared first on Octafinance.